Startup profile · funding coverage
Tesorai funding, valuation and investors
Cloud proteomics platform that reprocesses raw mass-spectrometry data and compares results with curated research datasets.
Verified company research · funding, investors and latest developments
Keep track of Tesorai
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$5.3M · November 18, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$5.3M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · San Diego, California, USA
Investors in latest funding
Other: Perplexity Fund , IQT , South Central Ventures , New Stack Ventures , NextGen Venture Partners , f7 Ventures , VitalStage Ventures , ZAKA
Overview
San Diego-based Tesorai was founded by Melissa Miao, Peter Cimermancic and Charlie Kim, former Google/Verily colleagues. It provides Tesorai Search for data-dependent and data-independent mass-spectrometry searches, Tesorai Chat for quality control and downstream analyses, and Trove for curated public proteomics datasets. The firm says it has biopharma/research contracts and collaborations with named institutions.
Prices for commercial licenses, revenue, retention and valuation are not disclosed; free platform access does not establish commercial pricing.
Why Tesorai is interesting
Its $5.3M November 18 seed brings funding to $8M; researchers can revisit raw experiments rather than rely only on published paper conclusions. A claimed Alzheimer's biomarker rediscovery is a preprint finding, not a diagnostic validation.
Product & use cases
Documented research workflow: (1) upload raw DDA/DIA mass-spectrometry files to Tesorai Search; (2) select reference database, modifications and search parameters; (3) process spectra to peptide/protein assignments; (4) use Chat to inspect QC/statistics and export results; (5) use Trove to retrieve and analyze comparable curated public studies to test whether a protein signal repeats. Users are bioinformaticians, pharma discovery teams and research labs. Tesorai handles raw data rather than replacing wet-lab experimentation or establishing a medical diagnosis.
- Reanalyze historical raw proteomics experiments with current identification models.
- Cross-validate protein biomarkers across distinct public brain or tissue studies.
- Prepare harmonized experimental feature data for biological AI training.
Key facts
- $5.3M seed announced November 18, 2026; cumulative $8M, investors named but no issuer-confirmed lead.
- Search / Trove / Chat support mass-spectrometry reanalysis and cross-study replication.
- The reported p-tau217 rediscovery derives from an August company preprint; independent biomarker validation remains necessary.
Funding history (newest first)
Seed
2026-11-18 $5.3M- Perplexity Fund (participant)
- IQT (participant)
- South Central Ventures (participant)
- New Stack Ventures (participant)
- NextGen Venture Partners (participant)
- f7 Ventures (participant)
- VitalStage Ventures (participant)
- ZAKA (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: Reprocessing raw spectra plus cross-study comparison may expose signals lost in older analysis pipelines. Proprietary model performance and claimed speedups require reproducible independent benchmarking.
Unlike literature search services, Tesorai describes raw-file reprocessing and cross-study comparison. Case studies are vendor-reported and may not generalize across instruments or sample types. Trial access is advertised, but subscription pricing remains unknown.
-
MaxQuant alternative
Established open-source proteomics analysis pipelines; typically more hands-on compute operations.
-
FragPipe alternative
Free modular mass-spectrometry processing ecosystem; compare statistical validation and portability.
-
DIA-NN alternative
Specialized DIA mass-spec identification and quantitation.
-
Proteome Discoverer incumbent
Commercial proteomics processing software with strong instrument ecosystem.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.